DUBLIN – Merck & Co. Inc. is paying €115 million (US$137 million) up front and up to €349 million more in milestones to acquire Rigontec GmbH, which is developing an RNA-based immuno-oncology therapy, based on turning on the retinoic acid-inducible gene I (RIG-I) innate immune pathway to achieve an antitumor effect.